163 related articles for article (PubMed ID: 25153672)
1. Frontline Systemic Therapy With Pemetrexed-Platinum in Nonsquamous Non-Small-Cell Lung Cancer With Asymptomatic Brain Metastases.
Alsidawi S; Chaudhary R; Karim NA
Am J Ther; 2017; 24(2):e111-e120. PubMed ID: 25153672
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review.
He G; Xiao X; Zou M; Zhang C; Xia S
Medicine (Baltimore); 2016 Aug; 95(32):e4401. PubMed ID: 27512852
[TBL] [Abstract][Full Text] [Related]
3. Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?
Kim KH; Lee J; Lee JI; Nam DH; Kong DS; Ahn YC; Park HC; Kwon OJ; Kim H; Chang MH; Yi SY; Ji SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2010 May; 68(2):258-63. PubMed ID: 19592127
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of High-Dose Pemetrexed Plus Cisplatin as First-Line Chemotherapy In the Treatment of Patients with Brain Metastases from Lung Adenocarcinoma.
He Q; Wang Y; Zou P; Wang Y; Xiu C; Zhang H; Chi N; Zou H; Xu J; Zhou S; Tao R
World Neurosurg; 2017 Mar; 99():758-762. PubMed ID: 27060518
[TBL] [Abstract][Full Text] [Related]
5. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation.
Cagney DN; Martin AM; Catalano PJ; Reitman ZJ; Mezochow GA; Lee EQ; Wen PY; Weiss SE; Brown PD; Ahluwalia MS; Arvold ND; Tanguturi SK; Haas-Kogan DA; Alexander BM; Redig AJ; Aizer AA
Radiother Oncol; 2018 Mar; 126(3):511-518. PubMed ID: 29398153
[TBL] [Abstract][Full Text] [Related]
6. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
7. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
[TBL] [Abstract][Full Text] [Related]
8. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Doebele RC; Spigel D; Tehfe M; Thomas S; Reck M; Verma S; Eakle J; Bustin F; Goldschmidt J; Cao D; Alexandris E; Yurasov S; Camidge DR; Bonomi P
Cancer; 2015 Mar; 121(6):883-92. PubMed ID: 25377507
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
[TBL] [Abstract][Full Text] [Related]
10. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer.
Zhang Q; Cai XW; Zhu ZF; Yu W; Liu Q; Feng W; Xue MC; Fu XL
Anticancer Drugs; 2015 Apr; 26(4):456-63. PubMed ID: 25646743
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.
Simon GR; Manegold C; Barker SS; Treat JA; Visseren-Grul C; Obasaju C
Clin Lung Cancer; 2013 Nov; 14(6):601-8. PubMed ID: 23921171
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial.
Galetta D; Cinieri S; Pisconti S; Gebbia V; Morabito A; Borsellino N; Maiello E; Febbraro A; Catino A; Rizzo P; Montrone M; Misino A; Logroscino A; Rizzi D; Di Maio M; Colucci G
Clin Lung Cancer; 2015 Jul; 16(4):262-73. PubMed ID: 25582493
[TBL] [Abstract][Full Text] [Related]
14. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
Moro-Sibilot D; Smit E; de Castro Carpeño J; Lesniewski-Kmak K; Aerts JG; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Girvan A; Visseren-Grul C; Schnabel PA
Lung Cancer; 2015 Dec; 90(3):427-32. PubMed ID: 26791802
[TBL] [Abstract][Full Text] [Related]
15. Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma.
Bailon O; Chouahnia K; Augier A; Bouillet T; Billot S; Coman I; Ursu R; Belin C; Zelek L; Des Guetz G; Levy C; Carpentier AF; Morere JF
Neuro Oncol; 2012 Apr; 14(4):491-5. PubMed ID: 22362813
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report.
Lee JS; Pisters KM; Komaki R; Glisson BS; Khuri FR; Schea R; Fossella FV
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-52-S12-55. PubMed ID: 9331122
[TBL] [Abstract][Full Text] [Related]
17. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Socinski MA; Langer CJ; Huang JE; Kolb MM; Compton P; Wang L; Akerley W
J Clin Oncol; 2009 Nov; 27(31):5255-61. PubMed ID: 19738122
[TBL] [Abstract][Full Text] [Related]
18. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
Schuler M; Wu YL; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist LV; Massey D; Zazulina V; Yang JC
J Thorac Oncol; 2016 Mar; 11(3):380-90. PubMed ID: 26823294
[TBL] [Abstract][Full Text] [Related]
19. [Brain metastases of non small cell lung cancers: systemic treatments].
Chaubet-Houdu M; Besse B
Bull Cancer; 2013 Jan; 100(1):95-8. PubMed ID: 23376611
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002.
Sakata S; Sasaki J; Saeki S; Hamada A; Kishi H; Nakamura K; Tanaka H; Notsute D; Sato R; Saruwatari K; Iriki T; Akaike K; Fujii S; Hirosako S; Kohrogi H
Oncology; 2015; 88(4):201-7. PubMed ID: 25502447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
